SYNERGISM FROM COMBINED IMMUNOLOGIC AND PHARMACOLOGIC INHIBITION OF HER2 IN VIVO

The monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib improve the clinical outcome of patients with HER2-overexpressing breast cancer. However, the majority of metastatic cancers will eventually progress suggesting the need for other therapies. Because HER2 overex...

詳細記述

保存先:
書誌詳細
主要な著者: Morse, Michael A., Wei, Junping, Hartman, Zachary, Xia, Wenle, Ren, Xiu-Rong, Lei, Gangjun, Barry, William T., Osada, Takuya, Hobeika, Amy C., Peplinski, Sharon, Jiang, Haixiang, Devi, Gayathri R., Chen, Wei, Spector, Neil, Amalfitano, Andrea, Lyerly, H. Kim, Clay, Timothy M.
フォーマット: Artigo
言語:Inglês
出版事項: 2010
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2856803/
https://ncbi.nlm.nih.gov/pubmed/19856307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.24995
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料